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Abstract
Background: Growing evidence emphasizes the relevance of sphingolipids for metabolism and immunity of
antigen-presenting cells (APC). APCs are key players in balancing tolerogenic and encephalitogenic responses in
immunology. In contrast to the well-known prominent effects of sphingosine-1-phosphate (S1P) on lymphocyte
trafficking, modulatory effects on APCs have not been fully characterized.
Methods: Frequencies and activation profiles of dendritic cell (DC) subtypes, monocytes, and T cell subsets in 35
multiple sclerosis (MS) patients were evaluated prior and after undergoing fingolimod treatment for up to
24 months. Impact of fingolimod and S1P on maturation and activation profile, pro-inflammatory cytokine release,
and phagocytotic capacity was assessed in vitro and ex vivo. Modulation of DC-dependent programming of naïve
CD4+ T cells, as well as CD4+ and CD8+ T cell proliferation, was also investigated in vitro and ex vivo.
Results: Fingolimod increased peripheral slanDC count—CD1+ DC, and monocyte frequencies remained stable.
While CD4+ T cell count decreased, ratio of Treg/Th17 significantly increased in fingolimod-treated patients over
time. CD83, CD150, and HLADR were all inhibited, but CD86 was upregulated in DCs after incubation in the
presence of fingolimod. Fingolimod but not S1P was associated with reduced release of pro-inflammatory cytokines
from DCs and monocytes in vitro and ex vivo. Fingolimod also inhibited phagocytic capacity of slanDCs and
monocytes. After fingolimod, slanDCs demonstrated reduced potential to induce interferon–gamma-expressing Th1
or IL-17-expressing Th17 cells and DC-dependent T cell proliferation in vitro and in fingolimod-treated patients.
Conclusions: We present the first evidence that S1P-directed therapies can act additionally as immunomodulators
that decrease the pro-inflammatory capabilities of APCs, which is a crucial element in DC-dependent T cell
activation and programming.
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Background
Multiple sclerosis (MS) is a chronic inflammatory dis-
ease of the central nervous system (CNS) that is medi-
ated mainly by activated pro-inflammatory CD4+ T
helper (Th) cells and cytotoxic CD8+ T cells [1, 2].
Growing evidence is available that suggest a role for
antigen-presenting cells (APC) in the pathogenesis of
MS via their extraordinary capacity for inducing and
expanding pro-inflammatory T cell populations [3, 4]. In
particular, dendritic cells (DC) play a crucial role in
regulating the balance between encephalitogenic and tol-
erogenic immunity in MS [5]. We recently demonstrated
the presence of 6-sulfo LacNAc+ (slan) DCs, which are
the major pro-inflammatory and most potent T cell-
activating DC populations, in active inflammatory MS
lesions. SlanDCs represent a new potential link between
innate and adaptive immunity in MS and are specifically
modulated by different MS therapies [6, 7]. As such, fu-
ture treatments should include targeted modulation of
selective DC and APC functions [8, 9].
Fingolimod (FTY) is the first approved oral therapy for
highly active relapsing remitting (RR) MS. Fingolimod
exerts its effect via modulation of the sphingosine-1-
phosphate (S1P)-receptor (S1PR) [10, 11]. Extensive data
on the mechanism of action of fingolimod demonstrate
its principal effects on T and B cell trafficking via im-
pairment of S1PR1-mediated recirculation, which results
in significantly reduced lymphocyte egress from lymph-
oid tissues into the general circulation [12]. In addition
to the effects on T and B cells, modulation of the innate
immune system, including actions on DCs, have been
proposed [13–17]. Sphingolipids and their G-protein-
coupled receptors appear to play an important role in
the modulation of the innate immune system. Addition-
ally, all of the known sphingolipid receptor-subtypes
(S1PR1-S1PR5) are apparently involved in the modula-
tion of function and metabolism of APCs [13, 18, 19].
Although the circulation of APCs is not primarily regu-
lated by the S1P-system, FTY and its active metabolite
FTY-phosphate (FTYP) appear to affect APC migration
into lymph nodes and tissues possibly via modulation of
inflammatory chemokines [18, 20–22]. However, human
data on effects of FTY on APC subsets in MS patients
are rare, and the detailed impact on pro-inflammatory
potential and DC-dependent T cell regulation lack de-
tailed understanding.
To gain novel insights into immunomodulatory effects
of FTY on innate immunity beyond the established ef-
fects on lymphocyte recirculation, we investigated the
FTY-stimulated ex vivo and in vitro modulation of fre-
quency and function of slanDC (the most potent pro-
inflammatory DC population) to evaluate the impact of
FTY on inflammatory and T cell regulatory properties.
Here, we present data on the impact of FTY on the
inflammatory properties of slanDCs and classical APCs




Blood samples of 35 RRMS patients diagnosed according
to the McDonald criteria were used to evaluate immu-
nomodulatory effects on APC during FTY treatment
(Table 1). Blood samples were drawn prior to and during
FTY treatment up to 24 months. Further blood samples
were collected of ten untreated RRMS patients with
stable disease course compared to ten RRMS patients
with stable disease after 12 months of FTY therapy to
perform additional ex vivo analyses. Blood of healthy do-
nors was collected for in vitro analyses.
All experiments were approved by the institutional re-
view board of the University Hospital of Dresden. All
donors gave their written informed consent.
Flow cytometric analysis
Preparation of blood cells and analysis by fluorescence-
activated cell sorting (FACS) have been performed by a
previously validated protocol defined by standard operat-
ing procedures (SOPs): Peripheral blood mononuclear
cells (PBMCs) were prepared by Ficoll–Hypaque (Bio-
chrom, Berlin, Germany) density centrifugation. Cell
surface staining was performed by using fluorescence-
labeled anti-CD3, anti-CD4, anti-CD8, anti-CD14, anti-
CD19, anti-CD40, anti-CD80, anti-CD83, anti-CD86,
anti-CD150, anti-HLADR (BD Biosciences, Heidelberg,
Germany), anti-BDCA1, anti-slan, or anti-CD39 (Milte-
nyi Biotec, Bergisch Gladbach, Germany) according to
the manufacturer’s instructions. Negative controls in-
cluded directly labeled or unlabeled isotype-matched ir-
relevant antibodies (BD Biosciences). For further
characterization of intracellular markers, PBMCs were
suspended in culture medium consisting of RPMI 1640
(Biochrom), 5% human AB serum (CC pro, Neustadt,
Germany), 2 mM L-glutamine, 100 U/ml penicillin, and
100 μg/ml streptomycin (Biochrom). Analysis of T regu-
latory cells (Treg cells) was performed directly, whereas
Th17 cells were stimulated with 10 ng/ml phorbol myr-
istate acetate (PMA, Sigma-Aldrich, Steinheim
Germany) and 1 μg/ml ionomycin (Sigma-Aldrich) in
the presence of 0.2 μM Monensin (Biomol, Hamburg,
Germany) for 6 h prior to analysis. For intracellular
characterization of IL-17, CD154, and FoxP3, cells were
fixed with fresh prepared fixation concentrate and
permeabilized with wash-permeabilization concentrate
(Fixation/Permeabilization Buffer Set, eBioscience).
Subsequently, cells were stained using fluorescence la-
beled anti-IL-17 (BioLegend, London, UK), anti-
CD154 and anti-FoxP3 antibody (both Miltenyi
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Biotec), or isotype-matched irrelevant antibody (BD
Biosciences). After the staining procedure, cells were
evaluated on a FACScan Calibur (BD Bioscience).
Exact preparation of the cells, staining protocol, and
procedure as well as adjustment and compensation of
the FACScan was established prior to first analysis of
samples. Complete blood cell count was performed
additionally to FACS analysis. No patients with lym-
phopenia <0.2 GPt/l or lower medical drug possession
rate >95% during fingolimod treatment were included
to guarantee reliable data.
Immunomagnetic cell sorting
Isolation of slanDCs was performed as described previ-
ously [6]. PBMCs were incubated with M-DC8 hybrid-
oma supernatant containing 10 μg/ml of antibody and
additional rat anti-mouse IgM paramagnetic microbeads
(Miltenyi Biotec). Cells were sorted on two columns via
Table 1 Patient characteristics
Patient Nr. Sex Age Disease duration [years] Pretreatment EDSS Stable disease course
1 F 23 3 Interferon-beta 1.5 Yes
2 F 54 9 None 2 Yes
3 M 28 4 Interferon-beta 1.5 Yes
4 M 33 14 Natalizumab 4 Yes
5 F 42 14 Glatiramer acetate 3 Yes
6 F 53 16 Interferon-beta 3.5 Yes
7 F 47 3 Interferon-beta 3 Yes
8 F 47 7 Interferon-beta 2 Yes
9 F 41 11 Interferon-beta 6 Yes
10 F 46 15 Natalizumab 4 Yes
11 F 42 2 None 1 Yes
12 F 19 2 None 1.5 Yes
13 F 30 11 Natalizumab 2 Yes
14 M 35 3 Glatiramer acetate 2 Yes
15 M 27 3 Glatiramer acetate 2 Yes
16 F 44 4 Interferon-beta 2.5 Yes
17 F 27 11 Natalizumab 2 No
18 F 29 15 Natalizumab 6 Yes
19 F 24 11 None 1 Yes
20 F 47 6 Glatiramer acetate 3 Yes
21 F 45 11 Glatiramer acetate 1.5 Yes
22 M 42 3 Glatiramer acetate 4 Yes
23 F 44 10 Interferon-beta 1.5 Yes
24 M 38 3 Glatiramer acetate 1.5 Yes
25 M 26 4 Interferon-beta 1.5 No
26 F 42 4 Glatiramer acetate 2 Yes
27 M 29 2 Glatiramer acetate 2 Yes
28 F 35 2 Glatiramer acetate 3 Yes
29 M 41 1 None 2 Yes
30 M 30 6 Interferon-beta 1.5 Yes
31 M 28 1 None 1.5 Yes
32 M 44 10 Interferon-beta 4 Yes
33 F 45 10 Interferon-beta 4 Yes
34 M 41 19 Natalizumab 3 Yes
35 F 33 8 Glatiramer acetate 2.5 Yes
Sex, age at FTY start, time from disease onset to FTY start, pretreatment, baseline EDSS, and disease course (stable versus not stable) are depicted
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the autoMACS device (Miltenyi Biotec, Bergisch Glad-
bach, Germany). CD1 + DC were sorted by depletion of
CD19+ cells first, followed by positive selection of
BDCA1+ using immunomagnetic separation according
to the manufacturer’s instructions (Miltenyi Biotec, Ber-
gisch Gladbach, Germany). CD14+ monocytes were iso-
lated by positive selection, and CD4+ T cells, CD8+ T
cells, and naive CD45RA + CD4+ T cells were isolated
by depletion using immunomagnetic separation (Milte-
nyi Biotec, Bergisch Gladbach, Germany). The purity of
the isolated cell populations was >95% as always
assessed by flow cytometry afterwards.
Cytokine assay
Sorted slanDCs, CD1 + DCs, and monocytes of un-
treated or FTY-treated patients were cultured for 24 h.
For the last 18 h, lipopolysaccharide (LPS, Sigma Al-
drich) was added to stimulate cytokine release by TLR4
activation; unstimulated cells served as control. Add-
itionally, cells of healthy controls and FTY-treated pa-
tients were maintained in the presence or absence of
30 ng/ml FTY, 30 ng/ml FTYP (Caltag, Buckingham,
UK), or 20 or 200 nM S1P (Sigma Aldrich) in culture
before LPS was added. Supernatants were collected, and
the concentration of tumor necrosis factor alpha (TNF-
alpha), IL-1beta, IL-6, IL-12, and IL-23 was determined
using a commercial ELISA kit (BD Biosciences) accord-
ing to the manufacturer’s instructions.
Maturation and activation profile
Sorted slanDCs, CD1+ DCs, and monocytes of healthy
controls or FTY-treated patients were cultured in the
presence or absence of 30 ng/ml FTY or 30 ng/ml FTY-
phosphate or 20 or 200 nM S1P in vitro. Cells were col-
lected and characterized with regard to surface activa-
tion and maturation markers by staining with
fluorescence labeled anti-CD40, anti-CD80, anti-CD83,
anti-CD86, anti-CD150, and anti-HLA-DR (BD Biosci-
ences). Cells were evaluated on a FACScan Calibur.
DC-depending T cell proliferation and programming
SlanDCs or CD1 + DCs of healthy controls were cul-
tured with or without 3 or 30 ng/ml FTY or FTYP for
6 h and washed with phosphate-buffered saline (PBS,
Sigma Aldrich). To evaluate T cell proliferation, allogen-
eic CD4+ T cells or CD8+ T cells were labeled with
carboxyfluorescein-di-acetate-N-succinimidylester
(CFSE, Molecular Probes, Eugene, USA) at a final con-
centration of 0.3 μM. Treated and untreated DCs (1 ×
104 cells/well) were co-cultured with CFSE-labeled allo-
geneic CD4+ T cells or CD8+ T cells (1 × 105 cells/well)
for 4 days. Cells were harvested, and proliferation was
calculated by CFSE-incorporation by flow cytometry and
quantified by cell division index (CDI). For ex vivo
analyses, slanDCs of FTY-treated patients compared to
healthy controls were co-cultured with CFSE-labeled
allogeneic CD4+ or CD8+ T cells of the same healthy
donor to compare different potentials to induce T cell
proliferation. To assess direct effects of FTY or FTYP on
T cells, sorted CFSE-labeled CD4+ T cells or CD8+ T
cells of healthy donors or FTY-treated patients were cul-
tured in the presence of 5 μg/ml human anti-CD3 and
1 μg/ml human anti-CD28 (both BD Bioscience) without
or with FTY or FTYP for 4 days. CFSE-incorporation
was evaluated and counted as described above.
To evaluate DC-dependent T cell programming, FTY
or FTYP pretreated and untreated slanDCs or CD1 +
DC (1 × 104 cells/well) of healthy controls were co-
cultured with allogeneic naïve CD45RA + CD4+ T cells
(1 × 105 cells/well) in the presence of LPS for 8 days.
Thereafter, T cells were stimulated with 10 ng/ml PMA
and 1 μg/ml ionomycin in the presence of 0.2 μM mon-
ensin for 4 h. For intracellular characterization of IFN-
gamma, IL-17 and IL-4 production, cells were fixed with
freshly prepared ice-cold 4% paraformaldehyde (Merck)
and permeabilized with 0.1% saponin (Merck) in PBS
containing 1% fetal calf serum (FCS, Biochrom). Subse-
quently, cells were stained using fluorescence-labeled
anti-IFN-gamma, anti-IL-17, and anti-IL-4 antibody or
isotype-matched irrelevant antibody (BD Biosciences).
After the staining procedure, cells were evaluated on a
LSR Fortessa (BD Bioscience). For ex vivo analyses,
slanDCs of FTY-treated patients compared to healthy
controls were co-cultured with naïve CD45RA+ CD4+ T
cells of the same healthy donor to compare different po-
tential in T cell programming. To compare impact of
FTY or FTYP on potential of polarization directly on T
cells, naïve CD45RA+ CD4+ T cells stimulated with
5 μg/ml human anti-CD3 and 1 μg/ml human anti-
CD28 treated without or with FTY or FTYP served as
control. Differentiation into Th1 T cells was induced by
adding 10 ng/ml human IL-12 and 10 μg/ml human
anti-IL4, whereas Th2 differentiation was ensured by
adding 10 ng/ml human IL-4 and 10 μg/ml human anti-
IFN-gamma (all R&D Systems). After 8 days of cell cul-
ture, T cells were prepared and analyzed as described
above.
Phagocytosis assay
Sorted slanDCs, CD1+ DCs, and CD14+ monocytes of
healthy donors were maintained for 12 h in the presence
or absence of 3 ng/ml or 30 ng/ml of FTY or FTYP in
culture. To analyze, phagocytotic ability cells were
treated with 1 μm carboxylate-modified yellow–green
fluorescent FluoSpheres beads (Thermo Fisher Scientific,
MA, USA) for 60 min at 37 °C. After cells were washed
with PBS, incorporation of beads was evaluated by
FACScan Calibur.
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Apoptosis assay
Sorted slanDCs, CD1 + DCs, and CD14+ monocytes of
healthy donors were cultured for 24 or 48 h in the pres-
ence or absence of different concentrations of FTY or
FTYP (3 ng/ml; 30 ng/ml). Annexin was measured using
a FITC-labeled antibody (BD Bioscience) to determine
apoptosis at early stage, and APC-labeled fixable viability
dye staining (BD Bioscience) was used to evaluate apop-
tosis at late stage characterized by DNA fragmentation.
After, staining cells were analyzed by FACScan Calibur.
Statistical analysis
For repeated measure testing, repeated measure ana-
lysis of variance (ANOVA) with Bonferroni’s correc-
tion for compared pairs was used. Analyses with
multiple comparisons but not repeated testing were
evaluated by ANOVA with Bonferroni’s correction.
Analyses without multiple testing were assessed by
Student’s t test. Values of *p < 0.05, **p < 0.01, and
***p < 0.001 were considered significant.
Results
Increase in slanDC frequency in comparison to T cell
frequency changes in peripheral blood compartment
during long-term FTY treatment
In FTY-treated RRMS patients, there was a relative and
absolute increase of slanDCs frequency starting after
treatment initiation and during follow-up of 24 months
(Fig. 1a (A/B)). In contrast, CD1 + DCs and monocytes
increased in relative but not in absolute frequency
(Fig. 1a (C–F)). While CD4+ T cell levels significantly
decreased from the start of treatment on (Fig. 1a (G)),
there was a gradual reduction of the proportion of
CD154+ IL17+ Th17 cells over time. The proportion of
CD39+ FoxP3+ Treg cells gradually increased (Fig. 1a
(H/I)). Therefore, an increase in the ratio of Treg/Th17
could be observed during the first year of FTY treatment
(Fig. 1a (K)).
Decrease of activation/maturation markers and pro-
inflammatory cytokine secretion in slanDCs during long-
term FTY treatment
During FTY treatment, a decreased ex vivo surface ex-
pression of CD83, CD150, and HLADR on APCs over
the 24 months could be described (Fig. 1b). All DC sub-
sets showed an increase of CD86 (Fig. 1b (C/G)), which
remained unchanged in monocytes (Fig. 1b (L)). CD80
expression was downregulated in slanDCs but not in
CD1 + DCs and monocytes (Fig. 1b (D/H/M)). CD40
was unaffected in all investigated APC subsets (data not
shown).
SlanDCs of untreated RRMS patients presented with
higher levels of expression of IL-1beta, TNF-alpha as
well as IL-12 and IL-23 compared to cells from FTY-
treated patients (Table 2). In CD1 + DCs from FTY-
treated patients, there was no modulation of IL-12 and
IL-23 release upon stimulation compared to untreated
MS patients (Table 2). Production of IL-6 by slanDCs
and CD1 + DCs was lower in FTY-treated patients com-
pared with controls, but differences did not reach statis-
tical significance (Table 2). In monocytes from FTY-
treated patients, release of IL-1beta and TNF-alpha was
also inhibited, whereas IL-6 secretion was unchanged
(Table 2).
Different in vitro modulation of activation markers and
cytokine secretion by FTY and FTYP in different APCs
Evaluating effects of FTY or FTYP in vitro and sorted
APC of healthy controls were co-incubated with FTY
and FTYP: SlanDCs, but not CD1 + DCs, decreased
their CD83 expression in response to FTY and FTYP
(Table 3). Upregulation of activation marker CD150 in
treated monocytes was significantly impaired after FTY
or FTYP co-incubation compared with untreated con-
trols (Table 3). No significant alteration in HLADR,
CD86, CD80, or CD40 expression could be shown in
any investigated cells after FTY or FTYP co-culture in
vitro (Table 3).
In vitro addition of FTY and FTYP reduced IL-1beta,
IL-6, TNF-alpha, IL-12, and IL-23 secretion in slanDCs
compared with untreated controls (Table 3). Interest-
ingly, FTY exerted a stronger suppressive effect than
FTYP (Table 3). In CD1+ DCs, only IL-1beta and TNF-
alpha but not IL-12 and IL-23 cytokine production was
reduced by FTY and FTYP in vitro (Table 3). IL-6 was
inhibited significantly only by FTY (Table 3). Both FTY
and FTYP significantly inhibited pro-inflammatory in
vitro cytokine release of IL-1beta, IL-6, and TNF-alpha
in monocytes compared with untreated controls
(Table 3).
SlanDC are modulated by S1P in healthy donors but not
FTY-treated patients
In similar in vitro experiments, S1P modulated the ex-
pression of HLADR, CD86, and CD40 but not CD83 or
CD80 on slanDCs of healthy donors (Fig. 2a) or of sur-
face markers on CD1+ DCs and monocytes of healthy
controls (data not shown). Interestingly, in further ex
vivo analyses, sorted slanDCs of FTY-treated patients
that were cultured in the presence or absence of 20 or
200 nM S1P did not present any additional changes in
surface expression of activation or maturation markers
(Fig. 2b). Neither sorted CD1+ DC nor sorted mono-
cytes of FTY-treated patients were affected with respect
to the expression of surface markers after culture in the
presence of S1P (data not shown). There was no impact
of 20 or 200 nM S1P on pro-inflammatory cytokine re-
lease in sorted slanDCs, CD1+ DCs, or monocytes of
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Fig. 1 APC and T cell count in FTY-treated RRMS patients. a Relative and absolute cell count in slanDCs (A/B), CD1 + DCs (C/D), and monocytes (E/F) were
evaluated at baseline (BL), 4, 12, and 24 months (M) follow-up of 35 FTY-treated RRMS patients. In parallel absolute cell count of CD4+ T cells, proportion of
CD39 + FoxP3+ Treg cells and CD154 + IL17+ Th17 cells was examined (G–I). Ratio of Treg/Th17 is depicted (K). b Activation and maturation markers of APC
during FTY treatment. Expression of activation and co-stimulatory surface markers were analyzed at baseline (BL), 4, 12, and 24 months (M) in FTY-treated
RRMS patients in slanDCs (A–D), CD1 + DCs (E–H), and monocytes (I–M). Mean values ± SEM are presented. Bonferroni’s correction for compared pairs was
used for multiple testing. Asterisks indicate a statistically significant difference (*p< 0.05, **p< 0.01, ***p< 0.001)
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healthy controls or FTY-treated patients in vitro (data
not shown).
Modulation of DC-dependent T cell proliferation and
polarization in vitro and in FTY-treated patients without
any direct effects on T cells
In vitro pretreatment with FTY and, to a lower extent,
FTYP of slanDC and CD1 + DC demonstrated a decrease
in DC-dependent T cell proliferation in a dose-depending
manner in CD4+ Tcells rather than in CD8+ Tcells (Fig. 3a
(A–D)). FTY and FTYP pretreated sorted slanDCs and
CD1 + DCs were significantly inhibited in their ability to
promote their typical differentiation of naïve CD45RA+
CD4+ T lymphocytes into pro-inflammatory IFN-gamma-
expressing Th1 cells or IL-17-expressing Th17 cells (Fig. 3a
(E–H)), whereas pretreatment of CD1 + DCs with FTYP
showed no significant influence (Fig. 3b (G/H)). Differenti-
ation toward anti-inflammatory Th2 cells releasing IL-4
was not modulated by FTY or FTYP pretreatment of
slanDC or CD1 + DC in vitro (data not shown).
These results were mirrored in slanDCs of FTY-
treated patients ex vivo: SlanDCs of FTY-treated patients
induced less proliferation in allogenic CD4+ or CD8+ T
cells compared to slanDCs from healthy controls (Fig. 3b
(A/B)). Compared to healthy controls, slanDCs of FTY-
treated patients were impaired in their induction of dif-
ferentiation of naïve CD45RA+ CD4 T cells into pro-
inflammatory IFN-gamma-releasing Th1 cells or IL17-
releasing Th17 cells (Fig. 3b (C/D)), whereas differenti-
ation into Th2 cells was again unaffected (data not
shown).
In contrast, neither FTY nor FTYP directly affected
CD4+ or CD8+ T cell proliferation in vitro (Fig. 3c (A/
B)). FTY or FTYP did not directly affect any polarization
of naïve CD45RA+ CD4+ T lymphocytes into IFN-
gamma-expressing Th1 cells, IL-17 releasing Th17
(Fig. 3c (C/D)), or IL-4 releasing Th2 cells (data not
shown). Furthermore, CD4+ and CD8+ T cells of FTY-
treated patients demonstrated similar proliferative cap-
acity after CD3/CD28 stimulation compared to healthy
controls (Fig. 3d (A/B)).
FTY exerts differential effects on phagocytic function, but
not on apoptosis of APC
In slanDCs and monocytes, but not in CD1+ DCs,
phagocytic capacity was significant and dose depending
inhibited by FTY and FTYP (Fig. 4a (A–C)). In contrast
to phagocytic function, neither FTY nor FTYP increased
apoptosis in any investigated APCs within all investi-
gated time intervals (Fig. 4b (A–C)).
Discussion
A growing number of studies highlight the relevance of
sphingolipids and their related pathways that regulate in-
nate immunity [13, 17, 18]. Due to their characteristic
properties of antigen uptake and antigen presentation to
T cells, DCs are particular key players in balancing tol-
erogenic and immunogenic immune responses [5]. Many
studies hint at the importance of APCs, and particularly
DCs, in the pathogenesis of MS by virtue of the initi-
ation and perpetuation of T cell responses in periphery
as well as in the CNS [3, 6–9]. Growing evidence sup-
ports the concept of distinct modulation of innate im-
mune cells in S1PR-focused therapies beyond their
effects on lymphocyte recirculation [14, 17, 18].
Table 2 Cytokine release of APC during FTY treatment
APC subtype Cytokine MS CTRL MS FTY p value
slanDC IL-1beta 13,992.8 (+/−3452.7) 3762.3 (+/−1773.8) <0.01
IL-6 68,729.8 (+/−22,461.7) 52,339.4 (+/−23,723.3) n.s.
TNF-alpha 41,189.0 (+/−7526.0) 18,302.1 (+/−6363.5) <0.05
IL-12 484.9 (+/−99.3) 179.7 (+/−44.6) <0.05
IL-23 3298.2 (+/−990.9) 1304.6 (+/−326.2) <0.05
CD1 + DC IL-1beta 405.1 (+/−48.3) 255.7 (+/−57.4) <0.05
IL-6 7556.1 (+/−3401.0) 5270.4 (+/−2260.8) n.s.
TNF-alpha 1190.7 (+/−289.7) 653.1 (+/−19.6) <0.05
IL-12 166.1 (+/−54.0) 182.3 (+/−42.9) n.s.
IL-23 213.2 (+/−15.9) 188.7 (+/−28.8) n.s.
Monocytes IL-1beta 6517.8 (+/−1073.1) 4300.2 (+/−620.1) <0.05
IL-6 110,065.0 (+/−17,602.5) 106,537.0 (+/−23,730.0) n.s.
TNF-alpha 9018.8 (+/−2753.8) 4841.4 (+/−809.6) <0.05
Sorted slanDCs, CD1 + DCs, and monocytes of each ten untreated (MS CTRL) and FTY-treated (MS FTY) RRMS patients were stimulated to induce and analyze cyto-
kine release. Mean values of cytokines in picograms per milliliter are presented, and p values indicate level of statistical significance
n.s. not statistically significant
Thomas et al. Journal of Neuroinflammation  (2017) 14:41 Page 7 of 13
During long-term follow-up, the relative number of
peripheral slanDCs, CD1+ DCs, and monocytes in-
creased in FTY-treated patients. These effects are in line
with the redistribution of peripheral lymphocytes during
FTY treatment. But the absolute number of slanDCs also
increased. Expression of S1PR1-S1PR4 on monocyte-
derived DC surfaces has been investigated, and S1PR4
appears to be one of the dominant receptors subtypes in
that environment [19]. The impact of FTY and S1PR ag-
onists on APC migration are contradictory and seem to
depend on maturation and differentiation [18, 22, 23].
Some reports have shown an increase in peripheral DC
numbers in mice, combined with a decrease in the num-
ber of DCs in lymph nodes, thereby suggesting a
downregulation of CCR7—but not S1PR1—during FTY
treatment [18, 20, 22–24]. Additionally, reduced migra-
tion of DCs in the presence of certain chemokines after
FTY has been shown, and this indicates the possibility of
inhibited DC migration into the CNS in inflammatory
conditions such as those seen in active MS [20, 24]. Dif-
ferent studies demonstrated significant expression of
S1PR1-4 on human and murine DC subtypes [16, 23,
25]. Systemic FTY administration leads to a decrease in
expression of surface adhesion molecules and chemokine
receptors including CCR7, which are essential for a var-
iety of migratory processes [20, 23]. S1PR agonism im-
paired DCs in activation and differentiation, which is
important to upregulate adhesion molecules and
Table 3 Cytokine release and activation/maturation markers after FTY or FTYP in vitro
APC subtype Cytokine Without FTY p value FTYP p value
slanDC IL-1beta 26,753.7 (+/−13,156.6) 750.8 (+/−277.3) <0.05 6835.1 (+/−2634.6) <0.05
IL-6 69,634.3 (+/−18,883.2) 7180.5 (+/−1748.1) <0.05 46,643.9 (+/−8215.2) <0.05
TNF-alpha 18,837.0 (+/−9012.4) 1576.9 (+/−267.4) <0.05 5960.4 (+/−2131.8) <0.05
IL-12 637.7 (+/−141.8) 92.2 (+/−19.5) <0.01 312.8 (+/−153.3) n.s.
IL-23 4423.2 (+/−2068.8) 136.9 (+/−29.9) <0.05 1919.4 (+/−644.6) <0.05
CD1+ DC IL-1beta 624.4(+/−282.8) 266.2 (+/−37.1) <0.05 284.3 (+/−15.7) <0.05
IL-6 6889.3 (+/−1367.2) 1259.1 (+/−91.5) <0.01 5413.8 (+/−1100.4) n.s.
TNF-alpha 2203.0 (+/−1140.7) 933.9 (+/−387.3) <0.05 468.6 (+/−37.9) <0.05
IL-12 74.8 (+/−20.5) 66.4 (+/−6.6) n.s. 66.3 (+/−7.2) n.s.
IL-23 250.7 (+/−36.1) 251.2 (+/−61.7) n.s. 189.1 (+/−22.9) n.s.
Monocytes IL-1beta 8670.9 (+/−4065.2) 4902.8 (+/−1932.1) <0.05 599.8 (+/−113.4) <0.05
IL-6 105,741.0 (+/−24,004.5) 31,584.8 (+/−11,302.5) <0.05 32,223.6 (+/−8824.4) <0.05
TNF-alpha 2050.2 (+/−622.3) 1149.2 (+/−345.7) n.s. 705.1 (+/−164.8) <0.05
APC subtype Surface marker Without FTY p value FTYP p value
slanDC CD83 866.6 (+/−88.9) 426.8 (+/−34.5) <0.05 477.5 (+/−63.7) <0.05
HLADR 243.1 (+/−40,9) 254.7 (+/−56,7) n.s. 300.0 (+/−73,5) n.s.
CD86 681.6 (+/−115.1) 571.6 (+/−105.9) n.s. 670.3 (+/−105.4) n.s.
CD80 896.5 (+/−42.3) 812.5 (+/−39.1) n.s. 906.5 (+/−63.7) n.s.
CD40 510.0 (+/−72.9) 573.4 (+/−100.1) n.s. 542.5 (+/−90.2) n.s.
CD1 + DC CD83 720.9 (+/−135.9) 587.8 (+/−128.7) n.s. 707.0 (+/−111.3) n.s.
HLADR 405.3 (+/−94.0) 418.0 (+/−63.5) n.s. 327.4 (+/−75.7) n.s.
CD86 810.8 (+/−189.2) 703.3 (+/−64.8) n.s. 893.4 (+/−197.2) n.s.
CD80 632.8 (+/−61.7) 588.5 (+/−45.7) n.s. 601.5 (+/−23.6) n.s.
CD40 556.5 (+/−44.3) 650.0 (+/−75.6) n.s. 578.6 (+/−50.8) n.s.
Monocytes CD150 253.2 (+/−23.8) 80.7 (+/−8.3) <0.05 106.8 (+/−5.9) <0.05
HLADR 131.1 (+/−17.7) 177.0 (+/−36.5) n.s. 109.1 (+/−18.5) n.s.
CD86 295.8 (+/−27.0) 352.0 (+/−36.7) n.s. 243.6 (+/−25.9) n.s.
CD80 165.8 (+/−29.6) 171.3(+/−15.6) n.s. 162.8 (+/−22.4) n.s.
CD40 395.0 (+/−49.7) 459.5 (+/−58.2) n.s. 332.1 (+/−47.7) n.s.
Sorted slanDCs, CD1+ DCs, and monocytes of eight healthy donors were stimulated in the absence (without) or presence of 30 ng/ml FTY or FTYP. Release of pro-
inflammatory cytokines and expression of surface maturation/activation markers was then evaluated. Mean values of cytokines in picograms per millliliter or MFI
of surface expression are presented, Bonferroni’s correction was used for multiple testing, and p values indicate level of statistical significance
n.s. not significant
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chemokine receptors as well [16, 23]. Reduced expres-
sion of these markers contributes to a decreased homing
of DCs into lymphoid organs, but into inflamed tissues.
These findings indicate that DC migration is additionally
controlled by S1PRs and affected by S1PR-targeted ther-
apies that account for increase in peripheral absolute
DC count in our and recent study [20, 23]. Further stud-
ies are needed to investigate the exact effect of FTY and
its homologues on migration of slanDCs or other den-
dritic cells.
Due to the established effects of FTY on lymphocyte
recirculation, CD4+ T cell counts decreased in our FTY-
treated patients. But among CD4+ T cells exposed to
FTY, the proportion of Th17 cells was reduced, while
Treg cell numbers increased, thereby increasing the
Treg/Th17 cell ratio of cells. These data are in line with
previous reports of FTY use in patients that demon-
strated a re-balanced distribution of T cells by virtue of
decreased levels of effector T cells and increased levels
of Treg cells [26–28]. However, a direct or DC-
independent impact of FTY on T cell polarization or
proliferation in vitro could not be demonstrated [29]. As
APCs, and particularly DCs, are the most potent in-
ducers and regulators of T cell responses, the potential
modulation of DC function by FTY could be very
powerful.
Upon activation and antigen uptake, DCs maturate,
differentiate, and upregulate expression of surface
markers such as CD83 or CD150 and co-stimulatory
molecules including HLA-DR, CD86, CD80, or CD40.
During FTY treatment in our patients, chiefly slanDCs,
but also CD1 + DCs and monocytes, failed to maturate
and express the co-stimulatory marker HLA-DR. This is
in line with previous data [16, 21].
APCs that fail to differentiate or increase expression of
their co-stimulatory markers have impaired antigen
presentation and T cell activation properties, which may
lead to decreased induction of pro-inflammatory Th1/
Th17 cell responses. CD86 is upregulated during the dif-
ferentiation process on APCs, and there are some re-
ports suggesting its relevance for induction of tolerance
mechanisms in a range of immunological diseases [30].
In our analysis, the expression of CD86 was increased in
slanDCs and CD1+ DCs. These data are in concordance
with those previously presented for other DC subsets
[14].
Our data suggest distinct but straightforward modula-
tion of APC function by FTY treatment. In the literature,
data on DC surface markers during FTY treatment have
provided mixed results. Some studies did not find any
impact on surface expression, particularly in in vitro
studies [15, 16]. Other findings are in line with our re-
sults [14, 24, 31]. Certainly, in our analyses, impact of
FTY and FTYP on expression of co-stimulatory and
maturation markers was more pronounced in ex vivo
analyses compared to in vitro investigations. These dif-
ferences may be explained by the relatively shorter ex-
posure time for in vitro FTY and FTYP compared with
in vivo experiments. Human DCs present a pattern of
selective expression of S1PR1-4 with highest levels of
S1PR4 on immature DCs [16, 25]. Upon maturation, es-
pecially S1PR1 is upregulated whereas S1PR4 is slightly
decreased and S1PR2-3 are almost unaffected [16, 32].
After FTY exposure, expression of S1PR1 and S1PR4 is
reduced already after a short time period in human DCs
[16]. Further reports demonstrated direct modulation of
inflammatory and T cell stimulatory characteristics via
S1PR4 [33, 34]. FTY acts as unselective S1PR agonist
Fig. 2 Activation and maturation marker after S1P. a Sorted slanDCs (A–E) of healthy donors were cultured in the absence (without) or presence
of 2 or 200 nM S1P. Expression of activation and maturation surface markers was analyzed. b Sorted slanDCs (A–E) of FTY-treated MS patients
were cultured in the absence (without) or presence of 20 or 200 nM S1P. Expression of activation and maturation surface markers was analyzed.
Mean values ± SEM of eight individual experiments are presented. Bonferroni’s correction was used. Asterisks indicate statistically significant
difference (*p < 0.05)
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affecting S1PR1-5. Interestingly, compared to FTY,
findings on S1PR expression differ after treatment
with selective S1PR agonists in human DCs [20].
These results indicate that impact of FTY on DCs is
mediated by regulation of specific receptor expression
profiles as well as direct intracellular signaling after
S1PR agonism.
Interestingly, addition of S1P decreased surface ex-
pression of co-stimulatory molecules in slanDCs of
healthy donors, leaving other APS subtypes unaffected.
However, in FTY-treated patients, S1P-dependent modu-
lation of surface markers on slanDCs was abrogated.
These data further highlight slanDCs as distinct targets
in modulation of S1P pathways via S1PR, and distinct
from other APCs.
In addition to modulation of surface markers, further
FTY-stimulated inhibition of pro-inflammatory cytokines
was detected in slanDCs, CD1+ DCs, and monocytes
both in vitro and ex vivo. Previous reports have shown a
similar pattern of decrease of pro-inflammatory cyto-
kines by fingolimod in murine bone marrow-derived
DCs and induction of anti-inflammatory macrophages
[14, 15, 19, 24]. Furthermore and comparable to other
reports in mice, phagocytic capacity was inhibited in FTY-
treated slanDCs and monocytes in our study [15]. These
results suggest that FTY impairs important DCs
(See figure on previous page.)
Fig. 3 DC-dependent and independent T cell proliferation and programming. a SlanDCs or CD1+ DCs of healthy donors were pretreated with different
concentrations of FTY or FTYP and co-cultured with allogeneic CFSE-labeled CD4+ or CD8+ T cells. DC-depending proliferation was calculated by
CFSE-incorporation by flow cytometry and quantified by CDI. Proliferation after pretreatment is depicted in proportion to proliferation without pretreatment
(A–D). SlanDCs or CD1+ DCs of healthy donors were pretreated with different concentrations of FTY or FTYP and co-cultured with allogeneic naïve CD4+ T
cells. T cells were then analyzed regard their differentiation into pro-inflammatory IFN-gamma-expressing Th1 cells (E/F), IL-17-expressing Th17 cells (G/H).
Mean values ± SEM of eight individual experiments are presented. b In addition slanDCs of FTY-treated MS patients (DC FTY) and of healthy controls (DC
HC) were co-cultured with allogeneic CFSE labeled CD4+ or CD8+ T cells of the same donor. DC-dependent proliferation was calculated by CFSE-
incorporation by flow cytometry and quantified by CDI (A/B). SlanDCs of FTY-treated RRMS patients (DC FTY) and healthy controls (DC HC) were co-
cultured with allogeneic naïve CD4+ T cells of the same donor. T cells were then analyzed regard their differentiation into Th1 cells (C) and Th17 cells (D).
Mean values ± SEM of five different donors are presented. c DC-independent T cell proliferation and polarization. FTY- and FTYP-treated CFSE-labeled CD4+
or CD8+ T cells of healthy donors were stimulated with human anti-CD3/CD28. Proliferation was calculated by CFSE-incorporation by flow cytometry and
quantified by CDI (A–B). Polarization of FTY- and FTYP-treated naïve CD4+ T cells of healthy donors into IFN-gamma-expressing Th1 cells or IL-17-
expressing Th17 cells are depicted (G–H). Mean values ± SEM of six individual experiments are presented. d In addition, proliferation of CD4+ or C8+ T cells
of FTY-treated patients (CD4 FTY, CD8 FTY) compared to healthy controls (CD4 HC, CD8 HC) after anti-CD3/CD28 stimulation was evaluated (A/B). Asterisks
indicate a statistically significant difference (*p< 0.05, **p< 0.01, ***p< 0.001)
Fig. 4 Phagocytosis and apoptosis after FTY. a SlanDCs (A), CD1 + DCs (B), and monocytes (C) were treated with different concentrations of FTY or FTYP before
phagocytosis of carboxylate-modified yellow–green fluorescent beads was evaluated. Mean values ± SEM of eight individual
experiments are presented. Bonferroni’s correction was used. Asterisks indicate a statistically significant difference (*p<0.05, **p<0.01). b SlanDCs (A), CD1+ DCs
(B), and monocytes (C) were treated with different concentrations of FTY or FTYP for 24 h (A–C) or 48 h (data not shown).
Afterwards, apoptosis at early (gray bar) and late stage (white bar) was evaluated. Mean values ± SEM of eight individual experiments are presented
Thomas et al. Journal of Neuroinflammation  (2017) 14:41 Page 11 of 13
capabilities, which are important for antigen uptake and
processing as well as the pro-inflammatory destructive de-
myelinating process of the CNS in MS pathology [15, 35–
38].
IL-12 and IL-23 are known as essential regulators
in DC-depending Th1 and Th17 differentiation and
programming. The relevance of sphingolipids in IL-12
and IL-23 secretion in DCs and decreased expression
of IL-12 in bone marrow-derived DCs and
monocytes-derived DCs after FTY has been already
reported [15, 16, 18, 39–41]. However, slanDCs are
one of the most potent inducers of Th17 and Th1
cells [42, 43]. Our data demonstrate significant inhib-
ition of IL-12 and IL-23 secretion after FTY exposure
in vitro and ex vivo in slanDCs, but not in other
DCs. In addition, we were able to demonstrate that
FTY- or FTYP-treated slanDCs had reduced capacity
to induce Th17 and Th1 cells as well as T cell prolif-
eration in vitro. For the first time, these results could
be confirmed in ex vivo experiments using slanDCs
of FTY-treated patients. Th17 cells are known to be
reduced in peripheral blood and CNS during FTY
treatment [26–28]. Previous studies presented that
S1PR4 on DCs is critically involved in promotion of
Th17 cells [33].
We suggest that modulation of slanDCs by FTY treat-
ment promotes the reduction of pro-inflammatory T cell
activation and proliferation in MS. Effects on CD1+ DCs
were less pronounced. Other studies have demonstrated
a decrease in polarization of Th1 cells, but promotion of
Th2 cells by FTY-treated monocytes-derived DCs [16,
18, 19, 44]. Nevertheless, we could not identify increased
activation of IL-4-producing Th2 cells by FTY-treated
slanDCs or CD1+ DCs in vitro or ex vivo.
Conclusions
Our data demonstrate that S1PR-targeted therapies can act
additionally as immunomodulators that affect the innate
immune system beyond their established prominent effects
on lymphocyte trafficking. Our results highlight that FTY
can modulate essential DC-dependent pro-inflammatory T
cell-mediated pathways in MS immunology, which could
additionally contribute to the efficacy of FTY. These effects
appear to develop over the first year of treatment, which is
on a slower timescale than the instant effect of FTY on
lymphocyte distribution. Other mechanisms of action are
probably as well of importance because there is no direct
link between absolute lymphocyte counts and therapeutic
efficacy [45, 46]. In summary, we present supportive data
suggesting innate immune cells as additional important tar-
gets of S1PR-directed therapies for MS.
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